PoC Study of OBE022 in Threatened Preterm Labour

PHASE2UnknownINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

July 8, 2020

Study Completion Date

August 31, 2022

Conditions
Preterm Labor
Interventions
DRUG

OBE022

Oral

DRUG

Placebos

Oral

DRUG

Atosiban

I.V.

Trial Locations (18)

Unknown

Gynekologicko-porodnická klinika Fakultní nemocnice Brno, Brno

Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, Prague

Ústav pro péči o matku a dítě, Prague

Helsinki Universisty Hospital, Helsinki

Hilel Yafe Medical Center, Maternal Fetal Unit, Haifa

Rambam Medical Center, Maternal Fetal Unit, Haifa

Meir Medical Center, Obstetrics and Gynecology Department, Kfar Saba

Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women, Petah Tikva

Moscow Regional Perinatal Center, Balashikha

Kazan State Medical University, Kazan'

City clinical hospital № 15 named after O. M. Filatov of Healthcare Department of Moscow, Moscow

Perinatal center of the City Clinical Hospital #24, Moscow

Hospital La Paz, Madrid

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

Hospital Clínico Universitario de Santiago, Santiago de Compostela

Hospital Universitari i Politècnic La Fe, Valencia

Hanoi Obstetrics and Gynecology Hospital, Hanoi

My Duc Hospital, Ho Chi Minh City

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Scope International AG

INDUSTRY

collaborator

Iqvia Pty Ltd

INDUSTRY

collaborator

Cytel Inc.

INDUSTRY

collaborator

PhinC Development

INDUSTRY

lead

ObsEva SA

INDUSTRY